← All trials
NCT05917145
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 28, 2029
- First posted
- Jun 23, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 67
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.